12.-14. November 2024
Boston, USA
- Pressemitteilung
- Konferenzwebsite
- CureVac stailored LNP platforms to deliver mRNA for prophylactic and therapeutic applications
- Development of a multiepitope mRNA cancer vaccine for glioblastoma - first results of Phase I human study
- An mRNA based FimH ferritin nanoparticle vaccine against UPEC is highly immunogenic in rodents
- mRNA sequence parameters and formulation optimization increase mRNA therapeutics performance
- Enhancing TCRtg T cell therapy efficacy in solid tumors using mRNA-based vaccination